Open Access Policy:
All articles published in the journal Cancer Research and Therapy Connect are Gold Open Access, immediately available without any embargo period, and licensed under the Creative Commons Attribution 4.0 (CC BY 4.0) license. This license facilitates the unrestricted dissemination of articles, encouraging widespread sharing and utilization of valuable research contributions.
Publication Frequency:
Cancer Research and Therapy Connect follows a continuous publication model and is licensed under Creative Commons Attribution 4.0 (CC BY 4.0).
Publication Charges:
There will be no article processing charges (APCs) for submissions made by December 31, 2026, and all articles will be published as Open Access. Furthermore, the journal does not levy any additional fees on authors, including editorial processing charges, language editing fees, colour charges, submission fees, membership fees, or any other supplementary charges.
Subject Categories:
Targeted Cancer Therapy, Immunotherapy, Precision Oncology
Article Template:
You are encouraged to use the template to format your article according to our guidelines. However, this is not mandatory, as our layout team will ensure all necessary adjustments are made after acceptance and prior to final publication.
Download Template
Target Audience:
Cancer Research and Therapy Connect provides a platform for researchers, clinicians, and industry experts to share insights, foster collaboration, and explore emerging directions in targeted and immune-based cancer treatment.
Ethics Statement:
All articles published by Cancer Research and Therapy Connect adhere strictly to the ethical guidelines suggested by the Committee on Publication Ethics (COPE). We execute a stringent peer-review procedure that meticulously assesses the originality, quality, and precision of the research we disseminate. We employ advanced tools to scrutinize the legitimacy of submitted content and maintain a firm zero-tolerance stance toward instances of plagiarism, data manipulation, or inappropriate authorship. For further details, please review our comprehensive Editorial Policies & Ethical Oversight.
Review Article
